

READING

DISEASES

- Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. *Nature* 2004; 430: 242 - 249.
- Layne, SP. Human Influenza Surveillance: the Demand to Expand. *Emerging Infectious Diseases* 2006; 12: 562 - 568.

IHR 2005

- White House. Homeland Security Presidential Directive/HSPD-21. October 18, 2007. <http://www.whitehouse.gov/news/releases/2007/10/20071018-10.html>
- Rodier G, et al. Global Public Health Security. *Emerging Infectious Diseases* 2007; 13: 1447 – 1452.
- World Health Organization; Western Pacific Region. International Health Regulations 2005: Guidance for national policy-makers and partners. 1–16 (2008).

METHODS

- None.

INTESTINAL WORMS

- Chan MS. The Global Burden of Intestinal Nematode Infections- Fifty Years On. *Parasitology Today* 1997; 13(11):438 - 443.
- Stepek G et al. Human gastrointestinal nematode infections: are new control methods required? *International Journal of Experimental Parasitology* 2006; 87(5):325 - 341.

PERTUSSIS

- Ward JI, Cherry JD, Chang S-J, et al. Efficacy of an Acellular Pertussis Vaccine among Adolescents and Adults. *New England J Medicine* 2005; 353: 1555-1563.
- Barlow WE, Davis, RL, Glasser, JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. *New England J Medicine* 2001; 345: 656-661.
- Hewlett EL, Edwards KM. Pertussis — Not Just for Kids. *New England J Medicine* 2005; 352: 1215-1222.

NEONATAL TETANUS

- Meegan ME, et al. Effects of neonatal tetanus mortality after a culturally-based health promotion programme. *Lancet* 2001; 358: 640-641.
- Vandelaer J, et al. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. *Vaccine* 2003; 21: 3442-3445.
- CDC. Tetanus surveillance — United States, 1998-2000. *MMWR* 2003; 52/SS-3: 1-8.

MEASLES

- Parker AA, Staggs W, Dayan GH, et al. Implications of a 2005 Measles Outbreak in Indiana for Sustained Elimination of Measles in the United States. *New England Journal Medicine* 2006; 355: 447-455.
- Benn CS, et al. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. *Lancet* 2002; 359: 1313-1314.
- Gay NJ. The Theory of Measles Elimination: Implications for the Design of Elimination Strategies. *Journal Infectious Diseases* 2004; 189: S27 - S35.
- Meissner HC, et al. Measles Vaccines and the Potential for Worldwide Eradication of Measles. *Pediatrics* 2004; 114: 1065-1069.

HEPATITIS B

- Hoofnagle, JH. Hepatitis B — Preventable and Now Treatable. *New England Journal of Medicine* 2006; 354: 1074 - 1076.
- CDC. Global Progress Toward Universal Childhood Hepatitis B Vaccination. *Morbidity Mortality Weekly Report* 2003; 52: 868-870.
- Poovorawan Y, et al. Epidemiology and prophylaxis of viral hepatitis: a global perspective. *J Gastroenterol Hepatol.* 2002 Feb;17 Suppl:S155-66.
- Poland GA, Jacobson RM. Prevention of Hepatitis B with the Hepatitis B Vaccine. *New England Journal Medicine* 2004; 351: 2832 - 2838.

MALARIA

- Mutabingwa TK, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. *Lancet* 2005; 365: 1474 - 1480.
- Richie, T. High road, low road? Choices and challenges on the pathway to a malaria vaccine. *Parasitology.* 2006;133 Suppl:S113-44.
- Panosian CB. Economic access to effective drugs for Falciparum Malaria. *Clinical Infectious Diseases* 2005; 40: 713 - 717.
- Olliaro P. Drug resistance hampers our capacity to roll back malaria. *Clinical Infectious Diseases* 2005; 41 (Suppl 4): S247 - S257.

TUBERCULOSIS

- Editorial. XDR-TB—a global threat. *Lancet* 2006; 362: 964.
- Agranoff D, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. *Lancet* 2006; 362: 1012 - 1021.
- Frieden TR, et al. Tuberculosis. *Lancet* 2003; 362: 887 - 899.

- Ormerod, LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. *Br Med Bull.* 2005 Jun 14;73-74:17-24.

CHOLERA

- Kosek M, et al. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. *Bulletin of the World Health Organization* 2003; 81: 197 - 204.
- Colwell RR, et al. Reduction of cholera in Bangladeshi villages by simple filtration. *Proc Natl Acad Sci USA* 2003; 100: 1051-1055.
- Hill DR, Ford L, Lallo DG. Oral cholera vaccines: use in clinical practice. *Lancet Infectious Diseases* 2006; 6: 361 - 49.

HIV/AIDS

- Layne SP, et al. The need for national HIV databases. *Nature* 1988; 333: 511 - 512.
- Layne SP, et al. Quantifying the infectivity of human immunodeficiency virus. *Proceedings National Academy of Science USA* 1989; 86: 4644 - 4648.
- Layne SP, et al. HIV requires multiple gp120 molecules for CD4-mediated infection. *Nature* 1990; 346: 277 - 279.
- Colgate SA et al. Risk behavior-based model of the cubic growth of acquired immunodeficiency syndrome in the United States. *Proc Natl Acad Sci USA* 1989; 86: 4793-4797.

ON-LINE

UNAIDS. 08 Report on the Global AIDS Epidemic. August 2008.
http://whqlibdoc.who.int/unaid/2008/9789291737116_eng.pdf

INFLUENZA

- Webster RG, et al. H5N1 Outbreaks and Enzootic Influenza. *Emerging Infectious Diseases* 2006; 12: 3 - 8.

- Kilbourne ED. Influenza Pandemics of the 20th Century. Emerging Infectious Diseases 2006; 12: 9 – 14.
- Tubenberger JK, Morens DM. 1918 Influenza: the Mother of All Pandemics. Emerging Infectious Diseases 2006; 12: 15 – 22.
- Monto AS. Vaccines and Antiviral Drugs in Pandemic Preparedness. Emerging Infectious Diseases 2006; 12: 55 – 60.
- Layne SP. Human influenza surveillance: the demand to expand. Emerging Infectious Diseases 2006; 12: 562 - 568.

###